Literature DB >> 3881017

Hemodialysis without anticoagulation.

P W Sanders, H Taylor, J J Curtis.   

Abstract

Heparin is usually employed as an anticoagulant during routine hemodialysis. In patients at high risk of bleeding, however, use of heparin significantly increases their morbidity and, presumably, mortality. Over 1 year, we performed 156 hemodialysis procedures successfully without heparin in the transplant dialysis unit. Twenty-eight patients were included in the study; 23 patients had received renal transplants and five patients were in the mouth dental extraction, and parathyroidectomy). Only one of these patients had a coagulopathy. No dialysis procedure produced or aggravated bleeding. Conversely, a coagulopathy was not induced or worsened by dialysis without heparin. A significant complication, defined as complete clotting of the artificial kidney with or without clotting in the lines, occurred in eight dialyses (5.13% of the total) and resulted in an average blood loss of 150 ml. Partial clotting of the dialyzer did not interrupt the procedure and occurred nine times (5.8% of the total). These results compare favorably with previously documented complications from low-dose and regional heparin.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3881017     DOI: 10.1016/s0272-6386(85)80132-3

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  9 in total

Review 1.  Unfractionated heparin for hemodialysis: still the best option.

Authors:  Robert E Cronin; Robert F Reilly
Journal:  Semin Dial       Date:  2010 Sep-Oct       Impact factor: 3.455

Review 2.  Acute renal failure in the intensive care unit. Part 2.

Authors:  H L Corwin; J V Bonventre
Journal:  Intensive Care Med       Date:  1988       Impact factor: 17.440

3.  Use and safety of heparin-free maintenance hemodialysis in the USA.

Authors:  Jenny I Shen; Aya A Mitani; Tara I Chang; Wolfgang C Winkelmayer
Journal:  Nephrol Dial Transplant       Date:  2013-04-05       Impact factor: 5.992

Review 4.  Use and safety of unfractionated heparin for anticoagulation during maintenance hemodialysis.

Authors:  Jenny I Shen; Wolfgang C Winkelmayer
Journal:  Am J Kidney Dis       Date:  2012-05-05       Impact factor: 8.860

5.  The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial.

Authors:  Christina U Lorentz; Erik I Tucker; Norah G Verbout; Joseph J Shatzel; Sven R Olson; Brandon D Markway; Michael Wallisch; Martina Ralle; Monica T Hinds; Owen J T McCarty; David Gailani; Jeffrey I Weitz; András Gruber
Journal:  Blood       Date:  2021-12-02       Impact factor: 22.113

6.  Avoidance of systemic anticoagulation during intermittent haemodialysis with heparin-grafted polyacrilonitrile membrane and citrate-enriched dialysate: a retrospective cohort study.

Authors:  Karlien François; Karl Martin Wissing; Rita Jacobs; Dries Boone; Kristine Jacobs; Christian Tielemans
Journal:  BMC Nephrol       Date:  2014-07-03       Impact factor: 2.388

7.  Inpatient hemodialysis without anticoagulation in adults.

Authors:  Sheena Sahota; Roger Rodby
Journal:  Clin Kidney J       Date:  2014-10-30

8.  Prospective Study of Routine Heparin Avoidance Hemodialysis in a Tertiary Acute Care Inpatient Practice.

Authors:  Sami Safadi; Robert C Albright; John J Dillon; Amy W Williams; Fares Alahdab; Julie K Brown; Amanda L Severson; Walter K Kremers; Mary Ann Ryan; Marie C Hogan
Journal:  Kidney Int Rep       Date:  2017-03-16

9.  Rationale and design of the HepZero study: a prospective, multicenter, international, open, randomized, controlled clinical study with parallel groups comparing heparin-free dialysis with heparin-coated dialysis membrane (Evodial) versus standard care: study protocol for a randomized controlled trial.

Authors:  Patrick Rossignol; Marc Dorval; Renaud Fay; Joan Fort Ros; Nathalie Loughraieb; Frédérique Moureau; Maurice Laville
Journal:  Trials       Date:  2013-06-01       Impact factor: 2.279

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.